What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to announce and provide access to Gilead Sciences' earnings press release for the fourth quarter and full year ended December 31, 2003, as well as to discuss the company's financial condition and results of operations for that period.

Why does Gilead use non-GAAP financial measures?

Gilead uses non-GAAP financial measures because management believes they provide a more useful perspective on ongoing operating results and trends by excluding certain items that are unusual in nature, size, or infrequency. This allows for a better understanding of the company's core business performance.

What specific items are being excluded from GAAP results to present non-GAAP figures?

The excluded items mentioned include an in-process research and development charge related to the Triangle Pharmaceuticals acquisition, reimbursement from a vendor contractual dispute settlement, and non-cash asset impairment charges and write-downs, as well as an income tax benefit.

Where can I find the detailed financial results?

The detailed financial results for the quarter and year ended December 31, 2003, are available in the press release filed as Exhibit 99.1 to this 8-K report.

GILD 8-K SEC Disclosure

Summary

Gilead Sciences, Inc. (GILD) filed an 8-K on January 29, 2004, to report its earnings for the quarter and year ended December 31, 2003. The report primarily directs investors to an accompanying press release (Exhibit 99.1) for detailed financial results and operational updates. Management emphasizes the use of non-GAAP financial measures to provide a clearer view of ongoing operational performance by excluding unusual or infrequent items.

Key Highlights

1Gilead Sciences reported its financial results for the fourth quarter and full year ended December 31, 2003, via a press release filed with the 8-K.
2The company utilizes non-GAAP financial measures in its reporting.
3Management believes non-GAAP measures offer crucial insights into core business trends by excluding specific, unusual items.
4Excluded items include an in-process R&D charge from the Triangle Pharmaceuticals acquisition (Q1 2003).
5Also excluded is a vendor contract dispute settlement reimbursement (Q3 2003).
6Non-cash asset impairment charges and write-downs, along with an income tax benefit from Q4 2003, are also presented on a non-GAAP basis.
7John F. Milligan, Executive Vice President and Chief Financial Officer, signed the report.

GILEAD SCIENCES, INC. 8-K Report (Jan 29, 2004)

Summary

Key Highlights

Frequently Asked Questions